摘要
利拉鲁肽是一种胰高血糖素样肽-1(GLP-1)类似物,通过激活GLP-1受体,以葡萄糖依赖性刺激胰岛素分泌并抑制胰高血糖素分泌,临床用于治疗2型糖尿病。本文综述利拉鲁肽的临床研究进展。
Liraglutide is an analogue of glucagon-like peptide-1(GLP-1).It can stimulate glucose-dependent insulin secretion and inhibit glucagon secretion by activating the GLP-1 receptor.Generally,liraglutide is used for treatment of type 2 diabetes.This review describes the progress in clinical studies of liraglutide.
出处
《世界临床药物》
CAS
2013年第5期312-315,共4页
World Clinical Drug